

Reference: FOI.ICB-2425/132

Subject: Continuous Glucose Monitoring Policy

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
<p>In 2022 NICE updated the guidance on the use of Continuous Glucose Monitoring (CGM). This guidance includes the use of CGM devices in people with T2 diabetes who fall under certain criteria.</p> <p>Please can you tell me:</p> <ol style="list-style-type: none"> Has your ICB adopted NG28 guidance for use of CGM in the T2 population that NICE recommend? <p>If yes, please can you provide the policy related to this?</p> <p>If no, what plans the ICB have to implement this updated guidance in to a policy and what timescales you are working to?</p> <ol style="list-style-type: none"> What reasons can you give for not implementing this guidance so far? If you are not willing to implement these NICE recommendations in full by the end of 2024 why would this be? 	<ol style="list-style-type: none"> The ICB has adopted NG28, we do not have a policy but have a 'clinical pathway for use of diabetes technologies in all patients with type 2 Diabetes' that is available on the BNSSG formulary website: https://remedy.bnssg.icb.nhs.uk/formulary-adult/local-guidelines/6-endocrine-system-guidelines/ N/A N/A

The information provided in this response is accurate as of 22 July 2024 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.